TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00048126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg po bid
Study: NCT02305823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study: NCT01288352

Intervention type: OTHER
Group type: OTHER
Intervention: early standardised rhythm control
Description: Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences.
Study: NCT03283254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Description: A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual (ETAU)
Description: Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate.
Study: NCT02445300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag Surgical dressing (study group)
Description: The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sofra-Tulle® dressing (control group)
Description: The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
Study: NCT01636570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Sugar Pill
Description: Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: 10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
Study: NCT02637232

Intervention type: OTHER
Intervention: Mirvaso® / Onreltea TM
Study: NCT00377871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biological heart valve prosthesis
Description: Two heart valve designs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biological heart valve prosthesis
Description: Two heart valve designs
Study: NCT03900624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
Study: NCT01340430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
Study: NCT01206257

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
Study: NCT01692405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviGo Bx™
Description: The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy sponge pad
Description: the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
Study: NCT02092922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, KSP (Eg5) inhibitor; intravenous
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: standard of care
Study: NCT04599699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
Study: NCT01395030

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FCH PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromethylcholine
Description: Undergo FCH PET/CT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FCH PET/CT
Study: NCT02079766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose
Study: NCT01658228

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil
Description: Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram
Description: Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine
Description: Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
Study: NCT02963025

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP level

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP level

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Use of recruitment maneuvers
Study: NCT02348983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching via Telephone
Description: Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
Study: NCT02923388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection Mecobalamin,
Description: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Pyridoxine hydrochloride
Description: Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline 1 ml
Description: Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill orally thrice daily for 5 weeks
Study: NCT04510285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
Study: NCT01044732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope
Description: Device used with colonoscope to provide second, retrograde view of the colon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Third Eye Retroscope
Description: Device used with colonoscope to provide second, retrograde view of the colon
Study: NCT04294108

Intervention type: OTHER
Intervention: Prolong in-hospital stay
Description: Patients have a longer length of hospital stay than the common recommendation.
Study: NCT03365882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HER-2 testing
Description: Central testing of HER-2 for eligibility

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HER-2 testing
Description: Central testing of HER-2 for eligibility
Study: NCT01101230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 1.5 oz almonds/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Almonds
Description: 1.5 oz almonds/day
Study: NCT03487107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181
Description: 100 mg capsule administered orally once daily
Study: NCT04332627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
Study: NCT04523818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo standard of care surgery
Study: NCT03006432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil continu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil continu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study: NCT04533022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 b.i.d.
Study: NCT04329208

Intervention type: DEVICE
Intervention: Transcranial doppler
Description: TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH.

Intervention type: DEVICE
Intervention: Transcranial doppler
Description: TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH.
Study: NCT02752126

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Esophageal-Sparing Intensity-Modulated Radiotherapy
Description: Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
Study: NCT00694551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly IC-LC
Description: Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly IC-LC
Description: Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly IC-LC
Description: Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
Study: NCT01790581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS
Description: The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
Study: NCT04513379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600mg
Description: EFV 600 mg per day given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: 2 tablets of EFV 200 mg per day given orally
Study: NCT00219830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based walking program
Description: Home-based walking program; included use of pedometer and daily walk diary
Study: NCT04586088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus Camrelizumab
Description: Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study: NCT00969800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleverin Gel
Description: Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Cleverin Gel
Description: Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
Study: NCT00981357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: PF-04457845 4 mg tablet once daily / matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: PF-04457845 4 mg tablet once daily / matched placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet twice daily / matched placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet twice daily / matched placebo
Study: NCT01666730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies